What are the differences between Xocova (tixagevimab + cilgavimab) and Paxlovid (nirmatrelvir + ritonavir) regarding their indications, dosing regimens, efficacy, and safety profiles for COVID‑19?

Comparison of Xocova and Paxlovid for COVID-19 Treatment

Critical Clarification: Xocova is NOT Tixagevimab-Cilgavimab

There appears to be confusion in the question—Xocova (ensitrelvir) is a different drug entirely from tixagevimab-cilgavimab (Evusheld). Tixagevimab-cilgavimab is a monoclonal antibody combination that WHO guidelines now recommend AGAINST for COVID-19 prevention due to obsolete efficacy against current variants 1. The evidence provided does not contain information about Xocova (ensitrelvir), so this comparison will focus on Paxlovid (nirmatrelvir/ritonavir), which has the strongest guideline support.

Paxlovid: The Gold Standard Oral Antiviral

Indications and Recommendations

For high-risk patients with non-severe COVID-19, Paxlovid receives a STRONG recommendation from WHO guidelines 2. This is the highest level of recommendation for any oral antiviral agent.

Risk-stratified recommendations:

• High risk of hospitalization: STRONG recommendation FOR use 2
• Moderate risk: CONDITIONAL recommendation FOR use 2
• Low risk: CONDITIONAL recommendation AGAINST use 2

Dosing and Administration

Per FDA labeling 3:

• Standard dose: Nirmatrelvir 300 mg (two 150 mg tablets) + ritonavir 100 mg, taken together twice daily for 5 days
• Moderate renal impairment (eGFR 30-59 mL/min): Reduced to nirmatrelvir 150 mg + ritonavir 100 mg twice daily for 5 days
• Severe renal impairment (eGFR <30 mL/min): NOT recommended
• Severe hepatic impairment (Child-Pugh C): NOT recommended
• Timing: Must initiate within 5 days of symptom onset 3

Efficacy Evidence

The evidence demonstrates robust benefits in appropriate populations:

High-risk patients 2:

• High certainty evidence of important reduction in hospitalization
• Moderate certainty evidence of mortality benefit
• Real-world data confirms 39% relative risk reduction in hospitalization and 61% reduction in death 4

Moderate-risk patients 2:

• Smaller but potentially important reduction in hospitalization
• No important mortality benefit (high certainty)

Standard-risk/vaccinated patients 5:

• No significant difference in time to symptom resolution (median 12 vs 13 days, p=0.60)
• Minimal hospitalization benefit in this population

Critical Drug Interactions

This is the most important practical limitation of Paxlovid 3:

The ritonavir component is a strong CYP3A4 inhibitor, creating potentially severe, life-threatening drug interactions. The FDA includes a BOXED WARNING about this 3.

Contraindications 3:

• Drugs highly dependent on CYP3A4 clearance where elevated levels cause serious harm
• Potent CYP3A4 inducers that would reduce Paxlovid efficacy

Before prescribing, you MUST:

1. Review ALL patient medications for CYP3A4 interactions
2. Determine if dose adjustments, temporary discontinuation, or additional monitoring is needed
3. Use the Liverpool COVID-19 drug interaction tool 2

Safety Profile

Common adverse effects 3:

• Dysgeusia (altered taste): Most common, reported in 5.8% 2
• Diarrhea: 2.1% 2

Serious concerns 3:

• Anaphylaxis and serious hypersensitivity reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Hepatotoxicity with transaminase elevations
• Risk of HIV-1 protease inhibitor resistance in undiagnosed HIV infection

Pregnancy considerations 2:

• Can be used in pregnancy when benefits outweigh risks
• No reports of serious adverse reactions in WHO Vigibase to date
• Uncertainty remains, but represents an option for pregnant patients at high risk

Comparative Positioning

Paxlovid is superior to alternatives 2:

• vs. Molnupiravir: Greater reduction in hospitalization (moderate certainty), without mutagenicity concerns 2
• vs. Remdesivir: Oral administration is far more practical than IV remdesivir 2

Key Clinical Pitfalls

1. Don't prescribe to low-risk patients: The evidence doesn't support benefit in vaccinated, standard-risk individuals 5

2. Don't miss drug interactions: This is the #1 reason for treatment failure or harm. Check EVERY medication 3

3. Don't delay treatment: Must start within 5 days of symptoms; earlier is better 3

4. Don't use in severe renal impairment: Contraindicated when eGFR <30 3

5. Don't forget renal dose adjustment: Reduce dose by 50% when eGFR 30-59 3

Practical Algorithm for Use

Step 1: Confirm COVID-19 diagnosis and symptom onset ≤5 days

Step 2: Risk stratify:

• High risk (age ≥65, immunocompromised, multiple comorbidities) → Proceed
• Moderate risk (1-2 risk factors, vaccinated) → Consider
• Low risk (young, healthy, vaccinated) → Do NOT use

Step 3: Check renal function:

• eGFR ≥60: Standard dose
• eGFR 30-59: Reduced dose
• eGFR <30: Do NOT use

Step 4: Review ALL medications for CYP3A4 interactions:

• Contraindicated interactions → Use alternative (molnupiravir or remdesivir)
• Manageable interactions → Adjust doses/hold medications temporarily
• No interactions → Proceed

Step 5: Prescribe 5-day course, counsel on dysgeusia and diarrhea